Clostridioides difficile Infection in Immunocompromised Pediatric Patients

Background

Clostridioides difficile infection (CDI) represents a significant clinical challenge in immunocompromised patients, particularly those with underlying hematologic and oncologic conditions. These patients are uniquely vulnerable due to compromised immune systems, frequent antibiotic and hospital exposures. Understanding the epidemiological characteristics, risk factors, and clinical outcomes of CDI in this specific patient population is crucial for developing targeted prevention and management strategies.

Methods

This retrospective, descriptive, cross-sectional study included a five-year period from August 2019 to September 2024. The research focused on immunocompromised patients under 16 years of age with confirmed Clostridioides difficile infection. Patients with underlying hematologic, oncologic, and bone marrow disorders were included.

The study employed descriptive statistical techniques to analyze the collected data. Categorical variables were evaluated using frequencies and percentages, while continuous variables were characterized by median values and interquartile ranges. Clinical characteristics, including disease severity, antibiotic exposure, and prior medical interventions, were meticulously documented and analyzed.

Results

The study cohort comprised 16 patients with a median age of 5.5 years. The 75% of patients had hematological neoplasms, while solid tumors represented 18.8% and bone marrow failure 6.3% of the cases (table 1). A substantial proportion of patients (37.5%) had previously undergone hematopoietic stem cell transplantation (HSCT). Disease severity was stratified as follows: mild to moderate in 31.3%, severe in 56.3%, and fulminant in 12.5% of episodes.

Notably, 87.5% of patients had received broad-spectrum antibiotic within the six weeks preceding the CDI episode. Carbapenems were administered in 81.3% of cases, and 56.3% received glycopeptide antibiotics for more than 72 hours. Twenty-five percent of patients had been admitted to the Pediatric Intensive Care Unit prior to the CDI episode (table 2).

Clinical outcomes were favorable in 75% of patients achieving clinical cure. However, CDI recurrence and associated mortality were observed in 12.5% of cases, underscoring the potential severity of the infection in this vulnerable patient population.

Conclusion

Clostridioides difficile infection emerges as a significant source of morbidity among immunocompromised pediatric patients. The study highlights the complex interplay between underlying medical conditions, antibiotic exposures, and infection outcomes. These findings emphasize the critical need for targeted risk assessment, prudent antibiotic stewardship, and specialized management strategies to mitigate the impact of CDI in this high-risk patient group.